Investors + Media

Investor Relations

Corporate Profile

Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Arvinas uses their proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC(R) protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.


Today's Open
Previous Close
Today's High
Today's Low
52 Week High
52 Week Low

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases
December 10, 2021
– ARV-471 continues to show a favorable tolerability profile and robust ER degradation in updated phase 1 dose escalation data presented at San Antonio Breast Cancer Symposium – – ARV-471 is expected to enter two Phase 3 registrational clinical trials in 2022 – NEW HAVEN, Conn. and NEW YORK, Dec.
November 10, 2021
NEW HAVEN, Conn., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Sean Cassidy, Chief Financial Officer, and Ian Taylor, Ph.D., Chief Scientific Officer,

Events + Presentations

There are no presentations at this time.